AVM Biotechnology hires executive team for Oncology & COVID-19 clinical trials

AVM Biotechnology | July 09, 2020

Seattle's AVM Biotechnology, an up-and-coming biotech firm whose lead molecule, AVM0703, has received FDA permission to begin clinical trials treating no-option Non-Hodgkin's Lymphoma and is applying to begin trials treating moderate-severely ill COVID-19 patients, announced today the hiring of Janet R. Rea, MSPH, as Chief Operating Officer. As COO, Rea will lead operations and direct regulatory affairs as the company conducts clinical trials and brings AVM0703 to market. "I am delighted that Janet Rea will join our team at AVM Biotechnology as the Chief Operating Officer. Having worked with Janet during a pivotal time at Protein Sciences while pursuing Flublok® FDA approval," said Dr. Manon Cox, AVM Biotechnology's Executive Board Member, "I know that her passion for quality and her tremendous experience in the transition from development into commercialization is exactly what we need at this crucial time at AVM now that our lead product is moving into the clinic." Janet R. Rea, MSPH, RAC, brings over 35 years of industry leadership experience in clinical development through commercialization in biologics and small molecules, with focus on oncology, infectious diseases, orphan and rare diseases. She obtained her B.S. in microbiology and M.S. in Public Health from the University of Washington. Her career in the healthcare industry began with then-American Hospital Supply Corporation (now Baxter), followed by Genetic Systems. Ms. Rea was an early employee of Seattle-based Immunex Corporation, where she played a key role in the company's first licensed product, Leukine®. She held positions with increasing levels of responsibility with MDS Pharma and Targeted Genetics, as well as executive positions with AVI BioPharma (now Sarepta), Poniard Pharmaceuticals and Protein Sciences Corporation (acquired by Sanofi), and Therapeutic Proteins International. Most recently, she was SVP of Regulatory, Quality and Clinical Affairs at Atossa Therapeutics (Genetics) with focus on breast cancer and COVID-19 therapy development. She has also operated a consulting practice to both small and large organizations and has lectured at the University of Washington for the Biomedical Regulatory Affairs Certificate and Master's Program, where she also served as a part–time Assistant Clinical Professor for two years. Ms. Rea will serve as a non-voting member of AVM's Board of Directors.

Spotlight

The crop protection industry is working to reduce the risk HHPs pose to people and the environment

Spotlight

The crop protection industry is working to reduce the risk HHPs pose to people and the environment

Related News

MEDICAL

Hillstream BioPharma to Announce Collaborating with Sapien Biosciences

Hillstream | June 30, 2022

Hillstream BioPharma, Inc., a U.S.-based biotechnology company developing novel therapeutic candidates targeting ferroptosis for cancer treatment, announced a collaboration with an Indian pioneer biobank and peonalized medicine company that leverages Saarum Innovation's global life sciences research expertise, Sapien Biosciences. The collaboration is aimed at assessing the compatibility of HSB-1216 with immune checkpoint inhibitors. HSB-1216, Hillstream’s most advanced candidate, is an IMCD modulator that targets various types of solid tumors. In an exhaustive study in Germany, the active drug in HSB-1216 was found to be efficacious in a clinical pilot for devastating cancers, including epithelial carcinomas and triple-negative breast cancer. Hillstream aims to build an early clinical proof-of-concept by beginning a clinical investigation with HSB-1216 in 2022. With this collaboration, Hillstream will be able to use Sapien’s patient samples and rich datasets to validate its HSB-1216 for the development of novel cancer therapeutics. We are initiating studies, in collaboration with Sapien Biosciences, to determine the synergy between HSB-1216, our ferroptosis inducer and nivolumab, an anti-PD1 antibody.” He stated, “In addition, we will also study the potential synergistic effects of HSB-1216 with the recently approved Bristol Myers Squibb drug Opdualag® (nivolumab + relatlimab), a fixed dose combination of an anti-PD1 MAb + anti-LAG3 MAb, to demonstrate that targeting a ferroptosis-associated metabolism in tumors may improve the efficacy of cancer immunotherapy.” Randy Milby, Hillstream’s Chief Executive Officer. We are excited to extend our collaboration with Hillstream Biopharma to evaluate potential synergy between their HSB-1216 molecule and ICIs using our expertise in establishing patient tissue-derived cell models in oncology, immunology and Immune-oncology Previously, Sapien demonstrated potent anti-cancer activity of HSB-1216 in primary triple negative breast cancer cells which were presented at AACR 2020.” Dr. Jugnu Jain, CEO, Sapien Biosciences.

Read More

MEDICAL

Nanoform Launches Technology that can form Biological Nanoparticles as Small as 50 nm and New Near-Term Business Target for 2021

Nanoform | November 27, 2020

Nanoform Finland Plc ("Nanoform"), an innovative nanoparticle medication empowering organization, today reported a proprietary technology that can frame biological nanoparticles as small as 50 nm and declared another close term business focus for 2021 to convey its first biologics Proof of Concept project for this new technology with a pharmaceutical or biotech partner. As drug molecules become more complex so do the alternatives to convey them. This complex nanoparticle formation technology gives want to improving the potential outcomes and probabilities of growing better medications for patients and it extends Nanoform's reach into the growing biological market. The technology is in its beginning phases of advancement and a patent application has recently been filed with the US Patent Office for the technology. As of today, Nanoform has two non-GMP lines on the biologics side notwithstanding the eight CESS® little atom nanoparticle innovation non-GMP lines.

Read More

MEDTECH

Medtronic Expands Minimally Invasive Spine Surgery Ecosystem with Next-Generation Spinal Technologies

Medtronic plc | October 01, 2021

Medtronic plc, the global leader in medical technology, today announced the latest additions to its minimally invasive spine surgery ecosystem, making it the only company to combine spinal implants, biologics, navigation, robotics, and AI-powered data to surgeons and patients. New additions to the Medtronic MIS+ portfolio include: Catalyft™ PL and PL40, the first releases in the new Catalyft™ Expandable Interbody System. Catalyft™ PL and PL40 feature a unique design for anterior rim engagement, a beveled tip for ease of insertion, seamless integration with StealthStation™ Navigation, simplified bone graft delivery, and active expansion at the precise angle and lift that surgeons need for minimally invasive, patient-specific solutions to meet sagittal alignment goals. The Space-D™ Access System, which enables pedicle-screw-based distraction, retraction and compression, compatible with Medtronic's leading MIS screw system, CD Horizon™ Solera™ Voyager™, enabling simpler, all-in-one access for surgeons, making procedures more efficient and reproducible. Accelerate™ Graft Delivery System with Grafton™ DBF enables more controlled and efficient delivery of graft material into the disc space or other locations. Accelerate enables placement of more bone graft2 to facilitate fusion and is nine-times faster than traditional graft delivery methods.3 Bone grafting is also more controlled and easier for surgeons to visualize. At Medtronic, we continue to raise the bar in minimally invasive spine surgery through our commitment to driving innovation and expanding our MIS capabilities, Our seamless integration of implants, instrumentation, and enabling technologies into a single ecosystem is helping surgeons remove variability in the surgical procedure, streamline and personalize care, and enable better patient outcomes. - Carlton Weatherby, vice president and general manager of Spine & Biologics within the Cranial & Spinal Technologies business Advancing Care with MIS+ TLIF More than 450,000 spinal fusion procedures4 are performed in the United States each year to reduce pain, improve stability, or correct deformities of the spine. About 200,000 are lower or lumbar fusion procedures,5 which treat conditions such as degenerative disc disease, herniated disc, fractured vertebrae, spinal stenosis, and other conditions. One of the most common spinal fusion procedures is transforaminal lumbar interbody fusion (TLIF). During a TLIF procedure, a disc is removed from the lumbar spine, and two vertebrae are joined together using screws or rods. An interbody fusion spacer is inserted into the space, and a bone graft or bone substitute is placed into the space. As the bone heals, it fuses the vertebrae together to form one bone. The new additions to Medtronic's MIS+ portfolio create the most complete MIS+ TLIF solution available for surgeons. A complete procedural solution allows surgeons to provide the benefits of minimally invasive spine care – including lower infection and complication rates,1 less blood loss,1 smaller incisions, reduced hospital stays,1 and less pain6 – to more patients. Compared to open TLIF, MIS+TLIF requires a smaller incision and less muscle and tissue disruption, which can mean a faster recovery time after the operation.7, 8, 9 Together, these technologies improve clinical and economic value while reducing OR time with a fully streamlined procedure1. About Medtronic Medtronic plc, headquartered in Dublin, Ireland, is among the world's largest medical technology, services, and solutions companies alleviating pain, restoring health, and extending life for millions of people around the world. Medtronic employs more than 90,000 people worldwide, serving physicians, hospitals, and patients in more than 150 countries. The company is focused on collaborating with stakeholders around the world to take healthcare Further, Together.

Read More